Taltz Side Effects
Generic name: ixekizumab
Note: This document provides detailed information about Taltz Side Effects associated with ixekizumab. Some dosage forms listed on this page may not apply specifically to the brand name Taltz.
Applies to ixekizumab: subcutaneous solution.
Serious side effects of Taltz
Along with its needed effects, ixekizumab (the active ingredient contained in Taltz) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ixekizumab:
More common
- body aches or pain
- burning, dry, or itching eyes
- chills
- cough
- difficulty with breathing
- discharge or excessive tearing
- ear congestion
- fever
- headache
- hoarseness
- itching in the genital or other skin areas
- loss of voice
- lower back or side pain
- painful or difficult urination
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- runny or stuffy nose
- scaling of the skin
- sneezing
- sore mouth or tongue
- sore throat
- unusual tiredness or weakness
- white patches in the mouth or on the tongue
Less common
- chest tightness
- diarrhea
- difficulty swallowing
- dizziness
- fast heartbeat
- general feeling of discomfort or illness
- hives, itching, skin rash
- joint pain
- loss of appetite
- muscle aches and pains
- nausea
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- shivering
- sweating
- trouble sleeping
- vomiting
Rare
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- rectal bleeding
- redness of the skin
- severe diarrhea
- severe stomach pain
Other side effects of Taltz
Some side effects of ixekizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For healthcare professionals
Applies to ixekizumab: subcutaneous solution.
General
Most commonly reported adverse reactions with a frequency of 1% or greater were injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Cardiovascular
- Common (1% to 10%): Hypertension
Dermatologic
- Common (1% to 10%): Urticaria, herpes simplex (mucocutaneous)
- Uncommon (0.1% to 1%): Angioedema, cellulitis, rash, eczema, pruritus, alopecia[Ref]
Gastrointestinal
- Common (1% to 10%): Nausea, diarrhea, oral herpes, pharyngitis, oropharyngeal pain
- Uncommon (0.1% to 1%): Oral candidiasis, inflammatory bowel disease, abdominal pain
- Rare (0.01% to 0.1%): Oesophageal candidiasis
- Frequency not reported: Crohn's disease, ulcerative colitis, gastroenteritis[Ref]
Genitourinary
- Common (1% to 10%): Vulvovaginal candidiasis, menstrual disorder, irregular menstruation, uterine dilation, curettage
- Uncommon (0.1% to 1%): Ovarian cyst
- Frequency not reported: Bacterial vaginosis, bartholinitis
Hematologic
- Very common (10% or more): Neutropenia (Up to 11%)
- Common (1% to 10%): Thrombocytopenia, anemia[Ref]
Hypersensitivity
- Frequency not reported: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria)[Ref]
Immunologic
- Very common (10% or more): Infections ( Up to 27%), immunogenicity (Up to 22%)
- Common (1% to 10%): Tinea infections, influenza
- Uncommon (0.1% to 1%): Serious infections[Ref]
Local
- Very common (10% or more): Injection site reactions (Up to 17%)
- Frequency not reported: Erythema, pain
- Postmarketing reports: Esophageal candidiasis[Ref]
Musculoskeletal
- Common (1% to 10%): Arthralgia, back pain, myalgia
- Uncommon (0.1% to 1%): Musculoskeletal pain, neck pain, non-cardiac chest pain
Nervous system
- Uncommon (0.1% to 1%): Headache, dizziness
Ocular
- Common (1% to 10%): Conjunctivitis
- Uncommon (0.1% to 1%): Iridocyclitis, eye pain[Ref]
Other
- Common (1% to 10%): Anti-drug antibodies development
- Uncommon (0.1% to 1%): Fatigue, pyrexia
Psychiatric
- Common (1% to 10%): Depression
Respiratory
- Very common (10% or more): Upper respiratory tract infections (including nasopharyngitis and rhinovirus infection) (Up to 16%)
- Uncommon (0.1% to 1%): Rhinitis, bronchitis, sinusitis[Ref]
Metabolic
- Uncommon (0.1% to 1%): Increased blood creatine phosphokinase, increased aspartate aminotransferase
Renal
- Common (1% to 10%): Dysuria
References
1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
2. Cerner Multum, Inc. "Australian Product Information."
3. (2016) "Product Information. Taltz Autoinjector (ixekizumab)." Eli Lilly and Company
Frequently asked questions
- What are monoclonal antibodies?
- How does Taltz compare to Cosentyx for psoriatic arthritis?
- What are 6 key Taltz side effects to watch out for?
- How long before Taltz works?
- Can I drink alcohol with Taltz?
- Is weight gain a side effect of Taltz?
- What are the new drugs for plaque psoriasis?
- What causes Plaque Psoriasis?
- How do you use the Taltz Autoinjector?
More about Taltz (ixekizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (211)
- Drug images
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Further information
Taltz side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.